Aytu Biopharma Inc reports results for the quarter ended December 31 - Earnings Summary

• Aytu Biopharma Inc AYTU.OQ reported a quarterly adjusted loss of 26 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -4 cents. The lone analyst forecast for the quarter was for a loss of 28 cents per share.

• Revenue fell 29.3% to $16.22 million from a year ago; analysts expected $15.55 million.

• Aytu Biopharma Inc's reported EPS for the quarter was 9 cents​.

• The company reported quarterly net income of $788 thousand.

• Aytu Biopharma Inc shares had fallen by 16.5% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 366.7% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Aytu Biopharma Inc is $8.00

This summary was machine generated from LSEG data February 12 at 09:50 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)